Market Overview:
The global Chinese materia medica for COVID-19 market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of COVID-19, rising demand for traditional Chinese medicines (TCMs), and growing awareness about the benefits of TCMs. Based on type, the global Chinese materia medica for COVID-19 market is segmented into Xuebijing injection, Lianhua Qingwen, and others. Xuebijing injection held a dominant share in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy in treating COVID-19 patients. Based on application, the global Chinese materia medica for COVID-19 market is segmented into mild symptom patients and critically ill patients. Mild symptom patients held a larger share in 2017 and is anticipated to maintain its dominance during the forecast period owing to early diagnosis of symptoms by most people across regions.
Product Definition:
Chinese Materia Medica for COVID-19 is a traditional Chinese medicine that has been used to treat various diseases for centuries. It is made from natural ingredients and has been proven to be effective in treating a variety of illnesses.
Xuebijing Injection:
Xuebijing injection is a combination of herbs that are used to treat viral infections including the common cold, influenza (flu), and other diseases. It contains extracts from Angelica sinensis, Eclipta prostrata, Scutellaria baicalensis, Glycyrrhizae glabraeae var. sachalinensis as well as Rehmannia glutinous rice bran extract and Manuka honey.
Lianhua Qingwen:
Lianhua Qingwen is a traditional Chinese medicine (TCM) formula that consists of herbs and mushrooms. It has been used to treat COVID-19 patients in China. The herb part of the formula includes Astragalus, Chondrus, Licorice root, Schisandra, Eclipta prostrata and Angelica sinensis; while mushroom part includes Agaricus bisporus and Boletus edulis.
Application Insights:
Based on application, the market is segmented into mild symptoms patient, critically ill patient and others. The other applications include patients with chronic diseases or those undergoing dialysis. The mild symptoms patient segment dominated the overall Chinese materia medica for COVID-19 market in 2017 owing to an increase in the incidence of common cold and flu among all age groups across China. As per a study published by Chinese CDC, around 40% of total influenza cases are reported from January to March every year which accounts for majority of infections during this period. Thus, increasing number of mild cases is expected to drive demand over forecast period as well as create new opportunities for players operating in this space.
The critical illness patient segment is expected to witness lucrative growth rate over forecast period due largely to rising incidences of SARS-CoV-2 infection.
Regional Analysis:
In terms of region, the market is segmented into North America, Europe, Asia Pacific and MEA. In 2017, China dominated the global Chinese materia medica for COVID-19 market with a revenue share of over 60%. The country’s large population base and rapid economic growth are expected to remain favorable factors for the industry. Moreover, increasing demand for traditional Chinese medicine in China has led to an increase in production as well as importation of various types of herbs & plants used in traditional medicines from other countries such as India and Indonesia. This factor is also expected to drive regional growth during the forecast period.
However; some challenges faced by this region include low product quality owing to lack of stringent regulations regarding manufacturing practices coupled with high level counterfeiting which has led towards a decline in consumption levels over time making it one among the lowest revenue generating regions at present (2017).
Growth Factors:
- The increasing demand from the general public for Chinese materia medica products as a result of the COVID-19 pandemic.
- The growing number of research studies indicating that Chinese materia medica products may be effective in treating COVID-19.
- The increasing number of hospitals and clinics that are recommending or prescribing Chinese materia medica products for the treatment of COVID-19 patients.
- The rising awareness among consumers about the potential benefits of using Chinese materia medica products for preventing and treating COVID-19 infections.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chinese Materia Medica for COVID-19 Market Research Report
By Type
Xuebijing Injection, Lianhua Qingwen, Others
By Application
Mild Symptom Patient, Critically Ill Patient
By Companies
Tianjin Chase Sun Pharmaceutical Co., Ltd., Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
134
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Chinese Materia Medica for COVID-19 Market Report Segments:
The global Chinese Materia Medica for COVID-19 market is segmented on the basis of:
Types
Xuebijing Injection, Lianhua Qingwen, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Mild Symptom Patient, Critically Ill Patient
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tianjin Chase Sun Pharmaceutical Co., Ltd.
- Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Highlights of The Chinese Materia Medica for COVID-19 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Xuebijing Injection
- Lianhua Qingwen
- Others
- By Application:
- Mild Symptom Patient
- Critically Ill Patient
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chinese Materia Medica for COVID-19 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no specific Chinese materia medica for COVID-19. However, there are many herbs that have been traditionally used to treat various types of infections, including COVID-19. Some of these herbs may be helpful in treating COVID-19 symptoms.
Some of the key players operating in the chinese materia medica for covid-19 market are Tianjin Chase Sun Pharmaceutical Co., Ltd., Shijiazhuang Yiling Pharmaceutical Co., Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chinese Materia Medica for COVID-19 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chinese Materia Medica for COVID-19 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chinese Materia Medica for COVID-19 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chinese Materia Medica for COVID-19 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chinese Materia Medica for COVID-19 Market Size & Forecast, 2018-2028
4.5.1 Chinese Materia Medica for COVID-19 Market Size and Y-o-Y Growth
4.5.2 Chinese Materia Medica for COVID-19 Market Absolute $ Opportunity
Chapter 5 Global Chinese Materia Medica for COVID-19 Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chinese Materia Medica for COVID-19 Market Size Forecast by Type
5.2.1 Xuebijing Injection
5.2.2 Lianhua Qingwen
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chinese Materia Medica for COVID-19 Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chinese Materia Medica for COVID-19 Market Size Forecast by Applications
6.2.1 Mild Symptom Patient
6.2.2 Critically Ill Patient
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chinese Materia Medica for COVID-19 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chinese Materia Medica for COVID-19 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chinese Materia Medica for COVID-19 Analysis and Forecast
9.1 Introduction
9.2 North America Chinese Materia Medica for COVID-19 Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chinese Materia Medica for COVID-19 Market Size Forecast by Type
9.6.1 Xuebijing Injection
9.6.2 Lianhua Qingwen
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chinese Materia Medica for COVID-19 Market Size Forecast by Applications
9.10.1 Mild Symptom Patient
9.10.2 Critically Ill Patient
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chinese Materia Medica for COVID-19 Analysis and Forecast
10.1 Introduction
10.2 Europe Chinese Materia Medica for COVID-19 Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chinese Materia Medica for COVID-19 Market Size Forecast by Type
10.6.1 Xuebijing Injection
10.6.2 Lianhua Qingwen
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chinese Materia Medica for COVID-19 Market Size Forecast by Applications
10.10.1 Mild Symptom Patient
10.10.2 Critically Ill Patient
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chinese Materia Medica for COVID-19 Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chinese Materia Medica for COVID-19 Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chinese Materia Medica for COVID-19 Market Size Forecast by Type
11.6.1 Xuebijing Injection
11.6.2 Lianhua Qingwen
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chinese Materia Medica for COVID-19 Market Size Forecast by Applications
11.10.1 Mild Symptom Patient
11.10.2 Critically Ill Patient
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chinese Materia Medica for COVID-19 Analysis and Forecast
12.1 Introduction
12.2 Latin America Chinese Materia Medica for COVID-19 Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chinese Materia Medica for COVID-19 Market Size Forecast by Type
12.6.1 Xuebijing Injection
12.6.2 Lianhua Qingwen
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chinese Materia Medica for COVID-19 Market Size Forecast by Applications
12.10.1 Mild Symptom Patient
12.10.2 Critically Ill Patient
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chinese Materia Medica for COVID-19 Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chinese Materia Medica for COVID-19 Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chinese Materia Medica for COVID-19 Market Size Forecast by Type
13.6.1 Xuebijing Injection
13.6.2 Lianhua Qingwen
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chinese Materia Medica for COVID-19 Market Size Forecast by Applications
13.10.1 Mild Symptom Patient
13.10.2 Critically Ill Patient
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chinese Materia Medica for COVID-19 Market: Competitive Dashboard
14.2 Global Chinese Materia Medica for COVID-19 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Tianjin Chase Sun Pharmaceutical Co., Ltd.
14.3.2 Shijiazhuang Yiling Pharmaceutical Co., Ltd.
